Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$17.07|
|52 Week High||US$15.86|
|52 Week Low||US$39.61|
|1 Month Change||-29.38%|
|3 Month Change||-20.79%|
|1 Year Change||-43.10%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-36.94%|
Recent News & Updates
How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?
If you want to know who really controls Kronos Bio, Inc. ( NASDAQ:KRON ), then you'll have to look at the makeup of its...
|KRON||US Biotechs||US Market|
Return vs Industry: KRON underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: KRON underperformed the US Market which returned 33.4% over the past year.
Stable Share Price: KRON is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: KRON's weekly volatility (7%) has been stable over the past year.
About the Company
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company’s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.
Kronos Bio Fundamentals Summary
|KRON fundamental statistics|
Is KRON overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|KRON income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.28|
|Net Profit Margin||0.00%|
How did KRON perform over the long term?See historical performance and comparison
Is Kronos Bio undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate KRON's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate KRON's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: KRON is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: KRON is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KRON's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KRON is good value based on its PB Ratio (2.3x) compared to the US Biotechs industry average (2.9x).
How is Kronos Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KRON is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KRON is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KRON is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KRON is forecast to have no revenue next year.
High Growth Revenue: KRON is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KRON's Return on Equity is forecast to be high in 3 years time
How has Kronos Bio performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: KRON is currently unprofitable.
Growing Profit Margin: KRON is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if KRON's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare KRON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KRON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: KRON has a negative Return on Equity (-30.18%), as it is currently unprofitable.
How is Kronos Bio's financial position?
Financial Position Analysis
Short Term Liabilities: KRON's short term assets ($424.3M) exceed its short term liabilities ($13.1M).
Long Term Liabilities: KRON's short term assets ($424.3M) exceed its long term liabilities ($34.6M).
Debt to Equity History and Analysis
Debt Level: KRON is debt free.
Reducing Debt: KRON had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KRON has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: KRON has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 74% each year.
What is Kronos Bio current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KRON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KRON's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KRON's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KRON's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KRON's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Norbert Bischofberger (65 yo)
Dr. Norbert W. Bischofberger, Ph D., is Director of Morphic Holding, Inc. since June 14, 2019. Dr. Bischofberger serves as a Director of Kronos Bio, Inc. since April 2018.He joined Kronos Bio in 2018 and...
CEO Compensation Analysis
Compensation vs Market: Norbert's total compensation ($USD15.15M) is above average for companies of similar size in the US market ($USD2.25M).
Compensation vs Earnings: Norbert's compensation has increased whilst the company is unprofitable.
Experienced Management: KRON's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: KRON's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: KRON insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.
Kronos Bio, Inc.'s employee growth, exchange listings and data sources
- Name: Kronos Bio, Inc.
- Ticker: KRON
- Exchange: NasdaqGS
- Founded: 2017
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$960.259m
- Shares outstanding: 56.25m
- Website: https://kronosbio.com
Number of Employees
- Kronos Bio, Inc.
- 1300 South El Camino Real
- Suite 300
- San Mateo
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 22:44|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.